Learn More About Janssen's Phase 3 COVID-19 Vaccine Candidate Clinical Trials Please note that by clicking this link, you’ll be leaving jnj.com and going to a third-party website not governed by the jnj.com privacy policy.
Johnson & Johnson is one of many companies hard at work on an investigational COVID-19 vaccine candidate, which includes recruiting adult participants around the world for our Phase 3 clinical trials known as ENSEMBLE. Please note that by clicking this link, you’ll be leaving jnj.com and going to a third-party website not governed by the jnj.com privacy policy.
A potential COVID-19 vaccine. Passionate efforts toward achieving racial and social justice. Smarter, more sustainable product packaging. These are just a few of the resolutions company change makers are aiming to bring to light this year—and they're already hard at work on them.
Tracking the spread of the virus in real time. Analyzing data to learn more about who's most vulnerable. These are just a couple of ways the company's data science team is helping inform how to respond to the pandemic.
As the J.P. Morgan Healthcare Conference takes place this week, the President of Johnson & Johnson Innovation – JJDC, Inc. shares some of the scientific breakthroughs and collaborations his team is championing to help address the unmet needs and well-being of people around the world.